Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma - PubMed (original) (raw)
Clinical Trial
. 2009 Sep 1;115(17):3944-54.
doi: 10.1002/cncr.24473.
Affiliations
- PMID: 19536884
- DOI: 10.1002/cncr.24473
Free article
Clinical Trial
Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma
Jeffrey S Weber et al. Cancer. 2009.
Free article
Abstract
Background: The primary objective of this phase 2 study was to assess the objective response rate (complete response [CR] + partial responses [PR]), by Response Evaluation Criteria in Solid Tumors, of PF-3512676, a CpG oligodeoxynucleotide, alone in 2 doses or in combination with dacarbazine (DTIC) in patients with unresectable stage IIIB/C or stage IV malignant melanoma, with the aim of selecting an arm to take forward to a phase 3 portion of the study.
Methods: A total of 184 patients were randomized to 1 of 4 treatments: PF-3512676 10 mg (low dose), at 40 mg (high dose), 40 mg plus DTIC (850 mg/m(2)), or DTIC (850 mg/m(2)) alone. Patients received PF-3512676 subcutaneously weekly in a 3-week cycle and received DTIC intravenously on the first week of the cycle.
Results: The objective response rate (PR or CR, confirmed or unconfirmed) in the 40 mg + DTIC arm was 16% (7 patients) compared with 8% (3 patients) with DTIC alone. One (2%) patient in the 10-mg and 0 patients in the 40-mg arms achieved an objective response. Best response of CR or PR or stable disease (SD), with no minimum duration defined for SD, was achieved by 15 (33%) patients in the 40 mg + DTIC arm, 15 (38%) patients in the DTIC-only arm, 8 (17%) patients in the 10-mg arm, and 9 (20%) patients in the 40-mg arm. The most frequently reported adverse events were classified as local injection site reactions or systemic flu-like symptoms, specifically fatigue, rigors, and pyrexia.
Conclusions: PF-3512676 at the doses used was generally well tolerated. The modest objective response rates observed in all arms did not warrant continuation to the phase 3 portion of the study.
Similar articles
- Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A, Garbe C, Stolz W, Ellwanger U, Seiter S, Dummer R, Ugurel S, Sebastian G, Nashan D, Linse R, Achtelik W, Mohr P, Kaufmann R, Fey M, Ulrich J, Tilgen W. Hauschild A, et al. Br J Cancer. 2001 Apr 20;84(8):1036-42. doi: 10.1054/bjoc.2001.1731. Br J Cancer. 2001. PMID: 11308250 Free PMC article. Clinical Trial. - Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
Serrone L, Zeuli M, Sega FM, Cognetti F. Serrone L, et al. J Exp Clin Cancer Res. 2000 Mar;19(1):21-34. J Exp Clin Cancer Res. 2000. PMID: 10840932 - Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, Saïag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzalez Larriba JL, Scherrer A, Menu Y. Avril MF, et al. J Clin Oncol. 2004 Mar 15;22(6):1118-25. doi: 10.1200/JCO.2004.04.165. J Clin Oncol. 2004. PMID: 15020614 Clinical Trial. - [Chemotherapy of malignant melanoma--current status].
Karg C, Garbe C, Orfanos CE. Karg C, et al. Hautarzt. 1990 Feb;41(2):56-65. Hautarzt. 1990. PMID: 2180855 Review. German. - Treatments for metastatic melanoma: synthesis of evidence from randomized trials.
Lui P, Cashin R, Machado M, Hemels M, Corey-Lisle PK, Einarson TR. Lui P, et al. Cancer Treat Rev. 2007 Dec;33(8):665-80. doi: 10.1016/j.ctrv.2007.06.004. Epub 2007 Oct 4. Cancer Treat Rev. 2007. PMID: 17919823 Review.
Cited by
- An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer.
Quiroga D, Wesolowski R, Zelinskas S, Pinette A, Benner B, Schwarz E, Savardekar H, Johnson C, Stiff A, Yu L, Macrae E, Lustberg M, Mrozek E, Ramaswamy B, Carson WE 3rd. Quiroga D, et al. Cancer Control. 2024 Jan-Dec;31:10732748241250189. doi: 10.1177/10732748241250189. Cancer Control. 2024. PMID: 38797949 Free PMC article. Clinical Trial. - Intratumoural immunotherapy: activation of nucleic acid sensing pattern recognition receptors.
Agrawal S, Kandimalla ER. Agrawal S, et al. Immunooncol Technol. 2019 Oct 16;3:15-23. doi: 10.1016/j.iotech.2019.10.001. eCollection 2019 Oct. Immunooncol Technol. 2019. PMID: 35757301 Free PMC article. Review. - Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency.
Li Z, Lai X, Fu S, Ren L, Cai H, Zhang H, Gu Z, Ma X, Luo K. Li Z, et al. Adv Sci (Weinh). 2022 Aug;9(22):e2201734. doi: 10.1002/advs.202201734. Epub 2022 Jun 2. Adv Sci (Weinh). 2022. PMID: 35652198 Free PMC article. Review. - B cells imprint adoptively transferred CD8+ T cells with enhanced tumor immunity.
Smith AS, Knochelmann HM, Wyatt MM, Rangel Rivera GO, Rivera-Reyes AM, Dwyer CJ, Ware MB, Cole AC, Neskey DM, Rubinstein MP, Liu B, Thaxton JE, Bartee E, Paulos CM. Smith AS, et al. J Immunother Cancer. 2022 Jan;10(1):e003078. doi: 10.1136/jitc-2021-003078. J Immunother Cancer. 2022. PMID: 35017148 Free PMC article. - Recent Advances in Oligonucleotide Therapeutics in Oncology.
Xiong H, Veedu RN, Diermeier SD. Xiong H, et al. Int J Mol Sci. 2021 Mar 24;22(7):3295. doi: 10.3390/ijms22073295. Int J Mol Sci. 2021. PMID: 33804856 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials